桑加莫生物科学 SGMO 深 沪
已收盘 09-26 16:00:00 美东时间
0.664
+0.031
+4.86%
华盛通- 最 高0.685
- 今 开0.65
- 成交量 708.29万股
- 最 低 0.6069
- 昨 收 0.6332
- 总市值 1.63亿
- 52周最高 3.179
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.4111
- 委 比 88.08%
- 总股本 2.45亿
- 历史最高 27.50
- 量 比 1.06
- 振 幅 12.33%
- 历史最低 0.2911
- 每 手 1
- 风险率 0.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多徘徊生死线上的Biotech，首席财务官辞职
近日，Sangamo Therapeutics的首席财务官Prathyusha Duraibabu通知公司，她决定辞去CFO职务，辞职将于2025年10月1日生...
09-23 12:03
Sangamo Therapeutics falls on CFO retirement
Shares of Sangamo Therapeutics (NASDAQ:SGMO) fell on Friday after the company's chief financial officer, Prathyusha Duraibabu, notified of her decision to resign, effective October 1. The resignation ...
09-12 21:03
Sangamo Biosciences CFO Resignation Announced
Sangamo Biosciences ( ($SGMO) ) has provided an announcement. On September 9, 2...
09-12 05:29
美股大行评级 | 潜在涨幅90.8%！Aris Mining获Canaccord Genuity升目标价至17美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Aris Mining"买入"评级，目标价从16.5美元升至17美元；花旗：维持Docusign"买入"评级，目标价从110美元升至115美元
09-05 09:40
Sangamo Biosciences Reveals Promising Fabry Disease Study Results
The latest announcement is out from Sangamo Biosciences ( ($SGMO) ). On Septemb...
09-04 20:29
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
<p>Sangamo Therapeutics announced positive results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for adults with Fabry disease. The study showed a favorable annualized eGFR slope at 52 weeks, stable cardiac function, and durable alpha-galactosidase A (α-Gal A) activity. Patients discontinued Enzyme Replacement Therapy (ERT) and experienced improved quality of life. The safety profile was favorable, with most...
09-04 12:05
GAMCO Natural Resources, Gold & Income Trust Increases Monthly Distribution 25%
GAMCO Natural Resources, Gold & Income Trust announced a 25% increase in its monthly cash distribution to $0.05 per share, effective October 2025. This increase reflects the Fund’s NAV total return of 28% year to date. The Fund invests primarily in equity securities of gold and natural resources companies and earns income through writing covered call options. The Fund is managed by Gabelli Funds, LLC. Investors should consider market risks and fl...
08-26 11:30
Sangamo Therapeutics Q2 EPS $(0.08) Misses $(0.05) Estimate, Sales $18.306M Miss $31.680M Estimate
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 48.15 percent. This is a 55.56 percent increase over losses of $(0.18) per share
08-08 04:08
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
